Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

O. V. Sintsova; E. V. Leychenko; I. N. Gladkikh; A. P. Kalinovskii; M. M. Monastyrnaya; E. P. Kozlovskaya

doi:10.1134/S1607672919060097

Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

Authors: Sintsova O.V.¹, Leychenko E.V.¹, Gladkikh I.N.¹, Kalinovskii A.P.¹^,2, Monastyrnaya M.M.¹, Kozlovskaya E.P.¹
Affiliations:
1. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences
2. School of Natural Sciences, Far Eastern Federal University
Issue: Vol 489, No 1 (2019)
Pages: 385-387
Section: Biochemistry, Biophysics, and Molecular Biology
URL: https://journal-vniispk.ru/1607-6729/article/view/213120
DOI: https://doi.org/10.1134/S1607672919060097
ID: 213120

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Recombinant analogue of the sea anemone Heteractismagnifica peptide was obtained, and the kinetic parameters of its interaction with mammalian α-amylases were determined. Magnificamide inhibits α-amylases significantly stronger than the medical drug acarbose (Precose^TM or Glucobay^TM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.